Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results

Company to provide business update on May 12 conference call

Apr. 20, 2026 at 12:03pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a collection of polished glass vials, test tubes, and other premium laboratory equipment arranged elegantly on a clean, monochromatic seamless background, conceptually representing Acurx Pharmaceuticals' focus on developing innovative antibiotics.Acurx Pharmaceuticals' pipeline of novel antibiotics aims to address the growing threat of difficult-to-treat bacterial infections.Staten Island Today

Acurx Pharmaceuticals, a late-stage biopharmaceutical company developing a new class of antibiotics, announced it will discuss its first quarter 2026 financial results and provide a business update on a conference call on May 12, 2026.

Why it matters

Acurx's lead antibiotic candidate, ibezapolstat, is preparing to advance into international Phase 3 clinical trials to treat patients with acute C. difficile Infection (CDI) and a trial targeting the prevention of recurrent CDI (rCDI). If successful, ibezapolstat could change the treatment paradigm for CDI and rCDI.

The details

The company will host the conference call at 8:00 am ET on Tuesday, May 12, 2026. Acurx's President and CEO, David P. Luci, and CFO, Robert G. Shawah, will discuss the results and provide a business update. Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS) antibacterial. The company has received final EMA and FDA agreement for its ibezapolstat pivotal Phase 3 trials in CDI.

  • The conference call will be held on Tuesday, May 12, 2026 at 8:00 am ET.

The players

Acurx Pharmaceuticals, Inc.

A late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections.

David P. Luci

President and Chief Executive Officer of Acurx Pharmaceuticals.

Robert G. Shawah

Chief Financial Officer of Acurx Pharmaceuticals.

Ibezapolstat

Acurx's lead antibiotic candidate preparing for advancement into international Phase 3 clinical trials to treat patients with acute C. difficile Infection (CDI) and for a trial targeting the prevention of recurrent CDI (rCDI).

Got photos? Submit your photos here. ›

What’s next

Acurx plans to begin international clinical trials for ibezapolstat as soon as possible, pending successful completion of the Phase 3 program.

The takeaway

Acurx's development of ibezapolstat, a novel antibiotic targeting C. difficile infections, represents a potential breakthrough in treating this difficult-to-treat condition and could change the treatment paradigm if successful in clinical trials.